Cancer Letters, 62 (1992) 257 – 260
Elsevier Scientific Publishers Ireland Ltd.

Subject Index

Volume 66

Aberrant crypts, oxysterols, cholesterol, bile acids, cell proliferation, colon carcinogenesis, 241
Asbestos, CD4, CD45RA, 99
AFB_1-induced GST-P positive hepatocytes, aflatoxin B_1, glutathione *S*-transferase placental form (GST-P), buthionine sulfoximine (BSO), 249
Aflatoxin B_1, cytochrome *P*-450, DNA binding, glutathione-conjugation, age-related, 69
Aflatoxin B_1, glutathione *S*-transferase placental form (GST-P), buthionine sulfoximine (BSO), AFB_1-induced GST-P positive hepatocytes, 249
Aflatoxin, food additives, turmeric, antioxidants, 115
Age-related, aflatoxin B_1, cytochrome *P*-450, DNA binding, glutathione-conjugation, 69
Aneuploidy, breast cancer, c-erbB-2, p53, flow cytometry, 193
Animal model, human T-lymphotropic virus type 1, synthetic peptide, vaccine, human, 11
Anti-inflammatory drugs, tobacco-specific nitrosamines, lung adenoma, 21
Anti-oncogene, tumor promoter, oncogene, cytokeratin, polymerase chain reaction, hepatoma, 155
Anti-phosphatidylinositol antibodies, cellular proliferation, avidity, specificity, cancers, hematological diseases, 35
Antibiotics, polyamine uptake, α-difluoromethylornithine, polyamine-deficient diet, antileukemic effect, 29
Anticancer action, droloxifene (3-hydroxytamoxifen), lipid peroxidation, tamoxifen, membrane antioxidant, breast cancer, 61
Anticarcinogens, oral carcinogenesis, diallyl sulfide, γ-glutamyl transpeptidase, unscheduled DNA synthesis, 207
Antileukemic effect, polyamine uptake, α-difluoromethylornithine, polyamine-deficient diet, antibiotics, 29
Antimutagenicity, polyphenolics, nitrosamine 4-(methylnitrosamino)-1- (3 puridyl) (NNK), carcinogenesis, 107
Antioxidants, aflatoxin, food additives, turmeric, 115
Antitumour activity, immunomodulatory peptide, tumour necrosis, Iscador, *Viscum album*, 123
Avidity, anti-phosphatidylinositol antibodies, cellular proliferation, specificity, cancers, hematological diseases, 35
Azoxymethane, retinoid, chemoprevention, intestine, rat, 93

Bacterial glutaminase therapy, Ehrlich ascites tumor, glutamine amidohydrolase, glutamine aminotransferase, mouse liver, mouse plasma, 225
Bile acids, oxysterols, cholesterol, aberrant crypts, cell proliferation, colon carcinogenesis, 241
Blood group H-antigen, squamous cell carcinoma, glycolipids, papillomavirus, rabbits, 175
Breast cancer cells, progesterone receptor, estrone sulfate, estradiol, progestagens, 55
Breast cancer, c-erbB-2, p53, aneuploidy, flow cytometry, 193
Breast cancer, calcium, growth factors, 131
Breast cancer, droloxifene (3-hydroxytamoxifen), lipid peroxidation, tamoxifen, membrane antioxidant, anticancer action, 61
Breast cancer, interferon-γ, indoleamine-2,3-dioxygenase, gynecologic cancer, tumor marker, 77
Breast cancer, oestrogen, progesterone, p29, cathepsin D, enzyme immunoassay, steroid binding assay, 183
Buthionine sulfoximine (BSO), aflatoxin B_1, glutathione *S*-transferase placental form (GST-P), AFB_1-induced GST-P positive hepatocytes, 249

C-erbB-2, breast cancer, p53, aneuploidy, flow cytometry, 193
Calcium, growth factors, breast cancer, 131
Cancers, anti-phosphatidylinositol antibodies, cellular proliferation, avidity, specificity, hematological diseases, 35
Carbohydrate, fucose, haptoglobin, ovarian cancer, 43
Carcinogenesis, antimutagenicity, polyphenolics, nitrosamine 4-(methylnitrosamino)-1-(3 puridyl) (NNK), 107
Cathepsin D, breast cancer, oestrogen, progesterone, p29, enzyme immunoassay, steroid binding assay, 183

CD4, CD45RA, asbestos, 99 CD45RA, CD4, asbestos, 99
Cell proliferation, oxysterols, cholesterol, bile acids, aberrant crypts, colon carcinogenesis, 241
Cellular proliferation, anti-phosphatidylinositol antibodies, avidity, specificity, cancers, hematological diseases, 35
Chemoprevention, retinoid, azoxymethane, intestine, rat, 93
Chloride current, multidrug resistance, intracellular pH, 83
Cholesterol, oxysterols, bile acids, aberrant crypts, cell proliferation, colon carcinogenesis, 241
Colon carcinogenesis, oxysterols, cholesterol, bile acids, aberrant crypts, cell proliferation, 241
Complete carcinogenesis, retinoic acid, retinoids, skin tumorigenesis, two-stage carcinogenesis, 233
Cytochrome *P*-450, aflatoxin B_1, DNA binding, glutathione-conjugation, age-related, 69
Cytokeratin, tumor promoter, oncogene, anti-oncogene, polymerase chain reaction, hepatoma, 155

Diallyl sulfide, oral carcinogenesis, anticarcinogens, γ-glutamyl transpeptidase, unscheduled DNA synthesis, 207
α-Difluoromethylornithine, α-polyamines, hormone-dependent and -independent breast cancer, 1
α-Difluoromethylornithine, polyamine uptake, polyamine-deficient diet, antibiotics, antileukemic effect, 29
DNA binding, aflatoxin B_1, cytochrome *P*-450, glutathione-conjugation, age-related, 69
Droloxifene (3-hydroxytamoxifen), lipid peroxidation, tamoxifen, membrane antioxidant, breast cancer, anticancer action, 61 Drug resistance, mitomycin C, lipid peroxidation, glutathione, 49

Early edema, 12-*O*-tetradecanoylphrobol-13-acetate, protein kinase C, okadic acid, staurosporine, 139
Ehrlich ascites tumor, bacterial glutaminase therapy, glutamine amidohydrolase, glutamine aminotransferase, mouse liver, mouse plasma, 225
Enzyme immunoassay, breast cancer, oestrogen, progesterone, p29, cathepsin D, steroid binding assay, 183
Estradiol, breast cancer cells, progesterone receptor, estrone sulfate, progestagens, 55
Estrone sulfate, breast cancer cells, progesterone receptor, estradiol, progestagens, 55

F344 rat, 6-mercaptopurine, promoting effect, *N*-ethyl-*N*-nitrosourea, 147
Flow cytometry, breast cancer, c-erbB-2, p53, aneuploidy, 193
Food additives, aflatoxin, turmeric, antioxidants, 115
Fucose, carbohydrate, haptoglobin, ovarian cancer, 43

Gamma glutamyltranspeptidase, protein intake, remodeling, persistence, preneoplastic foci, 165
Glutamine amidohydrolase, Ehrlich ascites tumor, bacterial glutaminase therapy, glutamine aminotransferase, mouse liver, mouse plasma, 225
Glutamine aminotransferase, Ehrlich ascites tumor, bacterial glutaminase therapy, glutamine amidohydrolase, mouse liver, mouse plasma, 225
γ-Glutamyl transpeptidase, oral carcinogenesis, anticarcinogens, diallyl sulfide, unscheduled DNA synthesis, 207
Glutathione *S*-transferase placental form (GST-P), aflatoxin B_1, buthionine sulfoximine (BSO), AFB_1-induced GST-P positive hepatocytes, 249
Glutathione, mitomycin C, lipid peroxidation, drug resistance, 49
Glutathione-conjugation, aflatoxin B_1, cytochrome *P*-450, DNA binding, age-related, 69
Glycolipids, blood group H-antigen, squamous cell carcinoma, papillomavirus, rabbits, 175
Growth factors, calcium, breast cancer, 131
Gynecologic cancer, interferon-γ, indoleamine-2,3-dioxygenase, breast cancer, tumor marker, 77

Haptoglobin, carbohydrate, fucose, ovarian cancer, 43
Hematological diseases, anti-phosphatidylinositol antibodies, cellular proliferation, avidity, specificity, cancers, 35
Hepatoma, tumor promoter, oncogene, anti-oncogene, cytokeratin, polymerase chain reaction, 155
Hormone-dependent and -independent breast cancer, α-polyamines, α-difluoromethylornithine, 1 Human T-lymphotropic virus type 1, synthetic peptide, animal model, vaccine, human, 11
Human, human T-lymphotropic virus type 1, synthetic peptide, animal model, vaccine, 11

Immunomodulatory peptide, antitumour activity, tumour necrosis, Iscador, *Viscum album*, 123
Indoleamine-2,3-dioxygenase, interferon-γ, gynecologic cancer, breast cancer, tumor marker, 77
Interferon-γ, indoleamine-2,3-dioxygenase, gynecologic cancer, breast cancer, tumor marker, 77
Intestine, retinoid, chemoprevention, azoxymethane, rat, 93
Intracellular pH, multidrug resistance, chloride current, 83

Iscador, immunomodulatory peptide, antitumour activity, tumour necrosis, *Viscum album*, 123

Lipid peroxidation, droloxifene (3-hydroxytamoxifen), tamoxifen, membrane antioxidant, breast cancer, anticancer action, 61
Lipid peroxidation, mitomycin C, glutathione, drug resistance, 49
Lipoproteins, phthalocyanine, purpurin, photodynamic therapy, tumours, 217
Lung adenoma, tobacco-specific nitrosamines, anti-inflammatory drugs, 21

Membrane antioxidant, droloxifene (3-hydroxytamoxifen), lipid peroxidation, tamoxifen, breast cancer, anticancer action, 61
6-Mercaptopurine, promoting effect, F344 rat, *N*-ethyl-*N*-nitrosourea, 147
Mitomycin C, lipid peroxidation, glutathione, drug resistance, 49
Mouse liver, Ehrlich ascites tumor, bacterial glutaminase therapy, glutamine amidohydrolase, glutamine aminotransferase, mouse plasma, 225
Mouse plasma, Ehrlich ascites tumor, bacterial glutaminase therapy, glutamine amidohydrolase, glutamine aminotransferase, mouse liver, 225
Multidrug resistance, intracellular pH, chloride current, 83

N-ethyl-*N*-nitrosourea, 6-mercaptopurine, promoting effect, F344 rat, 147
Nitrosamine 4-(methylnitrosamino)-1-(3 puridyl) (NNK), antimutagenicity, polyphenolics, carcinogenesis, 107

Oestrogen, breast cancer, progesterone, p29, cathepsin D, enzyme immunoassay, steroid binding assay, 183
Okadic acid, 12-*O*-tetradecanoylphrobol-13-acetate, protein kinase C, early edema, staurosporine, 139
Oncogene, tumor promoter, anti-oncogene, cytokeratin, polymerase chain reaction, hepatoma, 155
12-*O*-tetradecanoylphrobol-13-acetate, protein kinase C, okadic acid, early edema, staurosporine, 139
Oral carcinogenesis, anticarcinogens, diallyl sulfide, γ-glutamyl transpeptidase, unscheduled DNA synthesis, 207
Ovarian cancer, carbohydrate, fucose, haptoglobin, 43
Oxysterols, cholesterol, bile acids, aberrant crypts, cell proliferation, colon carcinogenesis, 241

p29, breast cancer, oestrogen, progesterone, cathepsin D, enzyme immunoassay, steroid binding assay, 183
p53, breast cancer, c-erbB-2, aneuploidy, flow cytometry, 193
Papillomavirus, blood group H-antigen, squamous cell carcinoma, glycolipids, rabbits, 175
Parathyroid hormone-related protein, Walker tumour, 201
Persistence, protein intake, remodeling, gamma glutamyltranspeptidase, preneoplastic foci, 165
Photodynamic therapy, phthalocyanine, purpurin, lipoproteins, tumours, 217
Phthalocyanine, purpurin, lipoproteins, photodynamic therapy, tumours, 217
Polyamine uptake, α-difluoromethylornithine, polyamine-deficient diet, antibiotics, antileukemic effect, 29
Polyamine-deficient diet, polyamine uptake, α-difluoromethylornithine, antibiotics, antileukemic effect, 29
α-Polyamines, hormone-dependent and -independent breast cancer, α-difluoromethylornithine, 1
Polymerase chain reaction, tumor promoter, oncogene, anti-oncogene, cytokeratin, hepatoma, 155
Polyphenolics, antimutagenicity, nitrosamine 4-(methylnitrosamino)-1-(3 puridyl) (NNK), carcinogenesis, 107
Preneoplastic foci, protein intake, remodeling, persistence, gamma glutamyltranspeptidase, 165
Progestagens, breast cancer cells, progesterone receptor, estrone sulfate, estradiol, 55
Progesterone receptor, breast cancer cells, estrone sulfate, estradiol, progestagens, 55
Progesterone, breast cancer, oestrogen, p29, cathepsin D, enzyme immunoassay, steroid binding assay, 183
Promoting effect, 6-mercaptopurine, F344 rat, *N*-ethyl-*N*-nitrosourea, 147
Protein intake, remodeling, persistence, gamma glutamyltranspeptidase, preneoplastic foci, 165
Protein kinase C, 12-*O*-tetradecanoylphrobol-13-acetate, okadic acid, early edema, staurosporine, 139
Purpurin, phthalocyanine, lipoproteins, photodynamic therapy, tumours, 217

Rabbits, blood group H-antigen, squamous cell carcinoma, glycolipids, papillomavirus, 175
Rat, retinoid, chemoprevention, azoxymethane, intestine, 93
Remodeling, protein intake, persistence, gamma glutamyltranspeptidase, preneoplastic foci, 165
Retinoic acid, retinoids, skin tumorigenesis, two-stage carcinogenesis, complete carcinogenesis, 233
Retinoid, chemoprevention, azoxymethane, intestine, rat, 93

Retinoids, retinoic acid, skin tumorigenesis, two-stage carcinogenesis, complete carcinogenesis, 233

Skin tumorigenesis, retinoic acid, retinoids, two-stage carcinogenesis, complete carcinogenesis, 233
Specificity, anti-phosphatidylinositol antibodies, cellular proliferation, avidity, cancers, hematological diseases, 35
Squamous cell carcinoma, blood group H-antigen, glycolipids, papillomavirus, rabbits, 175
Staurosporine, 12-*O*-tetradecanoylphrobol-13-acetate, protein kinase C, okadic acid, early edema, 139
Steroid binding assay, breast cancer, oestrogen, progesterone, p29, cathepsin D, enzyme immunoassay, 183
Synthetic peptide, human T-lymphotropic virus type 1, animal model, vaccine, human, 11

Tamoxifen, droloxifene (3-hydroxytamoxifen), lipid peroxidation, membrane antioxidant, breast cancer, anticancer action, 61
Tobacco-specific nitrosamines, lung adenoma, anti-inflammatory drugs, 21
Tumor marker, interferon-γ, indoleamine-2,3-dioxygenase, gynecologic cancer, breast cancer, 77
Tumor promoter, oncogene, anti-oncogene, cytokeratin, polymerase chain reaction, hepatoma, 155
Tumour necrosis, immunomodulatory peptide, antitumour activity, Iscador, *Viscum album*, 123
Tumours, phthalocyanine, purpurin, lipoproteins, photodynamic therapy, 217
Turmeric, aflatoxin, food additives, antioxidants, 115
Two-stage carcinogenesis, retinoic acid, retinoids, skin tumorigenesis, complete carcinogenesis, 233

Unscheduled DNA synthesis, oral carcinogenesis, anticarcinogens, diallyl sulfide, γ-glutamyl transpeptidase, 207

Vaccine, human T-lymphotropic virus type 1, synthetic peptide, animal model, human, 11
Viscum album, immunomodulatory peptide, antitumour activity, tumour necrosis, Iscador, 123

Walker tumour, parathyroid hormone-related protein, 201

Cancer Letters, 62 (1992) 261 – 262
Elsevier Scientific Publishers Ireland Ltd.

Author Index

Volume 66

Allameh, A. 69
Arnstein, H.R.V. 61
Ask, A. 29

Badger, B. 1
Baker, V. 183
Barker, S. 183
Behroozikha, M. 69
Biscozzo, L. 183

Campbell, A.M. 193
Campbell, T.C. 165
Cannon, M. 61
Castonguay, A. 107
Castonguay, A. 21
Chagnaud, J.-L. 35
Chen, L.-C. 233
Clark, J.S. 193

Dargan, E. 43
De Lucas, L.M. 233
Demers, L. 1
de Miguel, F. 201
Dezzutti, C.S. 11

Esbrit, P. 201
Etindi, R. 131

Fadierbe, S. 35

Garbo, G.M. 217
Gardner, P. 83
Geffard, M. 35
George, W.D. 193
Gollapudi, S. 83
Gopalan, P. 249
Greco, S. 183
Gschwendt, M. 139
Giuseppe, L. 183
Gupta, S. 83

Halliwell, B. 61
Heby, O. 29
Horiuchi, A. 249
Hyodoh, F. 99

Inoue, M. 175

Jalbert, G. 21
Jinlong, G. 93
Jones, C.S. 233
Jori, G. 217

Kaneko, Y. 155
Kang, N. 83
Kawakami, Y. 99
Kendall, C.W. 241
Kimura, M. 249
Kinugawa, K. 99
Kittstein, W. 139
Koo, M. 241
Korokawa, K. 155
Kuttan, G. 123
Kuttan, R. 115
Kuttan, R. 123
Kyogashima, M. 175

Lairmore, M.D. 11
Lal, R.B. 11
Lehmann, K. 249
Lennard, M.S. 61
Leung, B.S. 77
Lindner, D. 139
Line, D. 207
Lotikar, P.D. 249
Lu, J. 147

Maekawa, A. 147
Maity, P. 225
Manni, A. 131
Manni, A. 1
Marks, F. 139
Marsigliante, S. 183
Martel, J. 1
Matsushima, Y. 147
McDonald, T. 83
Mitsumori, K. 147
Morgan, A.R. 217
Mori, H. 93
Morishita, Y. 93

Nagabhushan, M. 207
Nagaoka, T. 147
Nakayama, J. 175
Nguyen, B.-L. 55

Onodera, H. 147

Pal, S. 225
Pasqualini, J.R. 55
Persson, L. 29
Polo, L. 217
Polverini, P.J. 207

Rajan, A. 115
Rao, A.V. 241
Reddi, E. 217
Roberts, B.D. 11
Rudolph, D.L. 11

Saidee, M. 69
Sato, K. 249
Seto, A. 175
Shaskan, E.G. 77
Singh, S.V. 49
Sly, L. 233
Smith, C. 61
Sokoloff, E. 241
Solt, D.B. 207
Soni, K.B. 115
Storelli, C. 183
Stout, L.E. 77
Sugie, S. 93

Tamai, Y. 93
Tanaka, T. 93
Teel, R.W. 107
Thompson, R.M. 77
Thompson, S. 43
Torihara, M. 93
Tsuji, K. 249
Tsukamoto, A. 155
Tsushima, H. 99
Turner, G.A. 43

Ueki, A. 99

Varin, C. 55
Vinson, G.P. 183

Watanabe, Y. 99
Wiseman, H. 61

Xu, B.H. 49

Yamaguchi, M. 99
Yamahara, J. 93
Yoshimi, N. 93
Youngman, L.D. 165